Envista (NYSE:NVST) SVP Mischa Reis Sells 9,675 Shares

Envista Holdings Corporation (NYSE:NVST) SVP Mischa Reis sold 9,675 shares of Envista stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total transaction of $290,250.00. Following the sale, the senior vice president owned 32,382 shares of the company’s stock, valued at approximately $971,460. The trade was a 23.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Envista Stock Performance

NVST opened at $30.19 on Thursday. Envista Holdings Corporation has a 1-year low of $14.22 and a 1-year high of $30.42. The stock has a market cap of $4.96 billion, a P/E ratio of 107.82, a P/E/G ratio of 2.06 and a beta of 1.01. The stock’s 50 day simple moving average is $23.36 and its 200 day simple moving average is $21.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04.

Envista (NYSE:NVST) last posted its earnings results on Thursday, February 5th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. The company had revenue of $750.60 million for the quarter, compared to the consensus estimate of $680.26 million. Envista had a return on equity of 6.54% and a net margin of 1.73%.Envista’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, equities analysts anticipate that Envista Holdings Corporation will post 1 EPS for the current fiscal year.

Envista News Summary

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Barclays raised its price target from $24 to $34 and moved NVST to an “overweight” rating, signaling stronger institutional conviction and giving the stock more upside momentum. Article Title
• Positive Sentiment: Short interest dropped ~23.3% in January to ~8.09M shares (about 5.0% of float, 3.1 days to cover), reducing one bearish force and removing a potential short-squeeze overhang. (Data reported 2/10/2026)
• Positive Sentiment: Zacks and other broker commentary have highlighted NVST as a buy/upgrade candidate amid sector rotation and AI-related market noise, reinforcing the positive analyst narrative around growth and execution. Article Title
• Positive Sentiment: Coverage highlighting Envista as a strong growth stock and noting that the name is gaining renewed focus as healthcare/NYSE composites strengthen, supporting continued investor interest. Article Title
• Neutral Sentiment: Mizuho raised its price target from $24 to $27 but kept a “neutral” rating — a modest improvement but still below the current market level, which may temper upside expectations for some investors. Article Title
• Negative Sentiment: Insider selling: SVP Mischa Reis sold 9,675 shares at about $30 (roughly $290K), reducing her stake by ~23%. Insider sales can create short-term nervousness about insider conviction even when not uncommon. SEC Filing

Analysts Set New Price Targets

Several research firms have recently commented on NVST. Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a research report on Monday, December 29th. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a report on Monday, January 26th. Wells Fargo & Company raised their price target on Envista from $21.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Friday, February 6th. William Blair upgraded Envista from a “hold” rating to an “outperform” rating in a research report on Friday, February 6th. Finally, Evercore reiterated an “outperform” rating and set a $32.00 price objective on shares of Envista in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $27.43.

Institutional Investors Weigh In On Envista

Hedge funds and other institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC raised its position in shares of Envista by 13.1% during the 4th quarter. Parallel Advisors LLC now owns 3,175 shares of the company’s stock worth $69,000 after buying an additional 367 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Envista by 2.9% during the fourth quarter. Deutsche Bank AG now owns 17,412 shares of the company’s stock valued at $378,000 after acquiring an additional 484 shares during the period. GAMMA Investing LLC raised its holdings in Envista by 34.3% during the third quarter. GAMMA Investing LLC now owns 2,498 shares of the company’s stock worth $51,000 after purchasing an additional 638 shares in the last quarter. Assetmark Inc. raised its holdings in Envista by 1.4% during the fourth quarter. Assetmark Inc. now owns 46,273 shares of the company’s stock worth $1,005,000 after purchasing an additional 659 shares in the last quarter. Finally, Claret Asset Management Corp lifted its position in Envista by 6.5% in the second quarter. Claret Asset Management Corp now owns 11,827 shares of the company’s stock worth $231,000 after purchasing an additional 724 shares during the period.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.